Zivo Bioscience, Inc. Cash Flow Statement
ZIVO|14 years of annual SEC 10-K data (FY2010-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 14 fiscal years. All figures from audited SEC 10-K filings.
Zivo Bioscience, Inc. used $4M in operating cash flow in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -96.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$13.4M | -$7.8M | -$8.7M | -$8.8M | -$9.1M | -$11.5M | -$14.6M | -$6.1M | -$5.8M | $680.8K | -$10.1M | -$3.2M | -$2.7M | -$7.1M |
| Depreciation & Amortization | - | - | - | $0 | $0 | $0 | $0 | $25.0K | $25.0K | $25.0K | - | $73.8K | $91.4K | - |
| Operating Cash Flow | -$4.3M | -$5.8M | -$7.1M | -$6.8M | -$2.6M | -$3.7M | -$5.0M | -$2.5M | -$2.3M | -$2.7M | -$3.0M | -$1.8M | -$1.3M | -$1.4M |
| Capital Expenditures | - | - | - | - | - | - | - | - | - | - | $0 | -$3.5K | -$4.7K | -$29.6K |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - | -$3.0M | -$1.8M | -$1.3M | -$1.4M |
| FCF Margin | - | - | - | - | - | - | - | - | - | - | - | - | -1241.1% | -1704.6% |